近日,重庆智翔金泰生物制药股份有限公司(智翔金泰)于上海证券交易所科创板上市,募集资金总额约为人民币34.73亿元,锦天城律师事务所为发行人提供法律意见。
智翔金泰成立于2015年,是一家创新驱动型生物制药企业,其主营业务为抗体药物的研发、生产与销售。
锦天城团队由高级合伙人张优悠律师领导。
本次发行的保荐人为海通证券。
AllBright on Genrix Biopharmaceutical’s listing on STAR Market
AllBright Law Offices has advised Chongqing Genrix Biopharmaceutical Co., Ltd. (Genrix Biopharmaceutical) on its $481 million IPO on Shanghai’s STAR Market.
Established in 2015, Genrix Biopharmaceutical is a biopharmaceutical company that engages in the research and development, production, and sale of antibody drugs in China.
The AllBright team was led by senior partner Zhang Youyou.
The sponsor of this project is Haitong Securities.